Education
About Us
Working with TipRanks
Follow Us
Illumina (ILMN)
NASDAQ:ILMN
ILMN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$68.70 - $156.66
Previous CloseN/A
Volume388.94K
Average Volume (3M)2.02M
Market Cap
$15.32B
Enterprise Value$16.33B
Total Cash (Recent Filing)$1.16B
Total Debt (Recent Filing)$2.52B
Price to Earnings (P/E)12.6
Beta1.35
Next Earnings
Oct 30, 2025EPS Estimate
1.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.19
Shares Outstanding153,700,000
10 Day Avg. Volume1,438,810
30 Day Avg. Volume2,017,856
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.07
Enterprise Value/Revenue3.81
Enterprise Value/Gross Profit5.73
Enterprise Value/Ebitda9.15
Forecast
1Y Price Target
$113.06Price Target Upside14.51% Upside
Rating ConsensusHold
Number of Analyst Covering19
Bulls Say, Bears Say
Bulls Say
Clinical AdoptionClinical now accounts for 53% of the total shipped, indicating growing clinical adoption.
Financial PerformanceMargins significantly exceeded expectations despite the impact of tariffs.
Stock BuybacksIllumina repurchased $380 million in shares, indicating confidence in its own value.
Bears Say
Competitive LandscapeThe slightly slower-than-expected NovaSeq X transition, coupled with an evolving competitive landscape, could be focal points for investors.
NovaX Transition ConcernsThe NovaX transition unexpectedly slowed, affecting future targets.
Proteomics Market PositionThe rationale of investing cash on a distant second competitor in the high-plex proteomics market is unclear when ILMN already has access to the NGS kit version of the assay via a partnership.
Illumina News
ILMN FAQ
What was Illumina’s price range in the past 12 months?
Illumina lowest stock price was $68.70 and its highest was $156.66 in the past 12 months.
What is Illumina’s market cap?
Illumina’s market cap is $15.32B.
When is Illumina’s upcoming earnings report date?
Illumina’s upcoming earnings report date is Oct 30, 2025 which is in 64 days.
How were Illumina’s earnings last quarter?
Illumina released its earnings results on Jul 31, 2025. The company reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.012 by $0.178.
Is Illumina overvalued?
According to Wall Street analysts Illumina’s price is currently Undervalued.
Does Illumina pay dividends?
Illumina does not currently pay dividends.
What is Illumina’s EPS estimate?
Illumina’s EPS estimate is 1.17.
How many shares outstanding does Illumina have?
Illumina has 153,700,000 shares outstanding.
What happened to Illumina’s price movement after its last earnings report?
Illumina reported an EPS of $1.19 in its last earnings report, beating expectations of $1.012. Following the earnings report the stock price went down -7.838%.
Which hedge fund is a major shareholder of Illumina?
Currently, no hedge funds are holding shares in ILMN
Illumina Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$113.06 (14.51% Upside)
$113.06 (14.51% Upside)
Blogger Sentiment
Bullish
ILMN Sentiment 80%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 81.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.14%
12-Months-Change
Fundamentals
Return on Equity
68.11%
Trailing 12-Months
Asset Growth
0.10%
Trailing 12-Months
Company Description
Illumina
Illumina, Inc. (ILMN) is a leading developer and manufacturer of life sciences tools and integrated systems for the analysis of genetic variation and function. Founded in 1998 and headquartered in San Diego, California, Illumina specializes in next-generation sequencing (NGS) technology, genotyping, and microarray solutions. Its products are primarily used in genomics research, clinical applications, and agricultural biotechnology, enabling advancements in personalized medicine, diagnostics, and drug discovery.
ILMN Company Deck
ILMN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected a mixed sentiment with several positive signs of growth in the clinical market and successful adoption of new platforms. However, challenges remain in the research market due to funding constraints and ongoing issues in China, resulting in a balanced perspective of the company's performance.View all ILMN earnings summariesILMN Revenue Breakdown
91.33% Sequencing
8.67% Microarray
ILMN Stock 12 Month Forecast
Average Price Target
$113.06
▲(14.51% Upside)
Technical Analysis
Ownership Overview
2.71% Insiders
30.85% Mutual Funds
1.05% Other Institutional Investors
42.60% Public Companies and Individual Investors